CER Could Be A Barrier To Innovation, Venture Capitalist Says
Comparative effectiveness research presents a barrier to innovation based on the uncertainty it creates within the payer community, Steven Burrill, CEO of venture capital firm Burrill & Co. said.
You may also be interested in...
Venture capitalists are taking a growing interest in the impact of comparative effectiveness research on future drug products and how results might affect products' ability to gain coverage by third-party payers
WellPoint has released guidelines for the submission and evaluation of comparative effectiveness research that it will use in reviewing drugs for its formulary
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.